AGTR1 and left ventricular hypertrophy: This study presents novel evidence that the AT1 receptor antagonist candesartan, at doses sufficient to reduce systolic arterial pressure and produce regression of left ventricular hypertrophy, does not result in regression of left atrial fibrosis in spontaneously hypertensive rats.